DOG 2022 (English)

DOG 2022 Keynote Lectures

Among the undisputed highlights at DOG 2022 in Berlin are the Keynote Lectures. Three highly ranking experts will dedicate their 30-minute talks to topics of importance not only to ophthalmology but to medicine and society in general.

Gene Therapy, Climate Change and Stem Cells – Keynote Lectures at DOG 2022

Keynote Lecture 29.9.2022

Gene therapy for retinal diseases
Robert MacLaren (Oxford, GB)

Professor Dr. Robert MacLaren, Professor of Ophthalmology at Oxford University, will kick things off with his keynote address on “Gene therapy for retinal diseases”. Based at the Oxford Eye Hospital and London’s Moorfields Eye Hospital, Professor MacLaren is a leading expert on ophthalmic translational medicine and a pioneer in both the development of retinal implants in retinitis pigmentosa therapy and robotic eye surgery. Professor MacLaren co-developed the world’s first retinal gene therapy for choroideremia and initiated the first gene therapy trial for retinitis pigmentosa.

Keynote Lecture 30.9.2022

Überhitzt – wie der Klimawandel unsere Gesundheit beeinträchtig
Claudia Traidl-Hoffmann (Augsburg)

Friday’s Keynote Lecture will be delivered by internationally renowned environmental physician Professor Dr. Claudia Traidl-Hoffmann. A specialist in dermatology, venereology and allergology, Professor Traidl-Hoffmann will speak on the topic of “Overheated – how climate change affects our health”. Professor Traidl-Hoffmann is Chair of Environmental Medicine at the Technical University of Munich and Director of the Outpatient Clinic for Environmental Medicine at Augsburg University Hospital. The scientist and author (“Overheated”) focuses on researching the effects of climate change on health and the need to develop resilience and adaptation strategies.

Keynote Lecture 1.10.2022

Application of cell therapy for limbal stem cell deficiency
Paolo Rama (Mailand, IT)

In our third and final Keynote Lecture, Professor Paolo Rama, MD, will give an overview of “Application of cell therapy for limbal stem cell deficiency” on Saturday. Paolo Rama is Professor of Ophthalmology at the University Vita-Salute San Raffaele in Milan and head of the Department of Corneal and Ocular Surface Diseases. His early research focused on the nerve growth factor, later, he turned to transplantation of cultured stem cells for corneal burns. Rama led the study for approval of the medical device Holoclar, the first commercial stem cell therapy in Europe.